January 18, 2008 08:30 AM Eastern Daylight Time
Azopharma Product Development Group and Accu-Break Pharmaceuticals, Inc. Announce Strategic Alliance Partnership
MIRAMAR, Fla., PLANTATION, Fla.--(BUSINESS WIRE)--Privately-held Azopharma Product Development Group, Inc. (“Azopharma”) and ACCU-BREAK Pharmaceuticals, Inc. (“ABP”) announced today the signing of a strategic alliance agreement in which Azopharma will become the “center of excellence” for developing products based on ABP’s innovative ACCU‑BREAK™ patented tablet technologies which allow for accurate and individualized dosage adjustment.
Dr. Allan Kaplan, CEO of ABP stated, “ABP’s patented ACCU‑BREAK technologies create an inactive break layer in tablets allowing them to be broken into accurate partial doses. By breaking at the inactive layer, accurate dose splitting can be guaranteed, since the active layer remains undisturbed. The ACCU-BREAK technologies have important implications for pharmaceutical companies as well as physicians and their patients.” Phil Meeks, CEO of Azopharma commented, “These new patented technologies will help pharmaceutical companies in many ways. From creating new products utilizing these novel technologies to gaining competitive market share by modifying existing products, we expect the pharmaceutical companies to be greatly affected by the ACCU‑BREAK technologies.”
For pharmaceutical companies, the ACCU-BREAK technologies also provide a solution for formulation challenges such as separating incompatible active ingredients to allow for the development of unique combination therapy products. For physicians, the ACCU‑BREAK technologies allow for greater flexibility in dose adjustment and greater safety in the dose titration process. For patients, the ACCU‑BREAK technologies are designed to assist them in following dosing instructions for splitting tablets with ease and accuracy.
Mr. Meeks continued, “We are excited to be the center of excellence for the development of products using ACCU-BREAK technologies. Our expertise in formulation and in total product development makes us the ideal partner for ABP.”
Azopharma & ACCU-BREAK Strategic Alliance Highlights:
- ACCU-BREAK technologies are U.S. patented until at least 2025.
- Strategic alliance agreement for five years between Azopharma Product Development Group and ACCU-BREAK Pharmaceuticals, Inc.
- Azopharma Product Development Group provides sales and marketing support for ACCU-BREAK technologies for five years.
- Patented tablet technologies provide solutions for pharmaceutical companies as well as physicians and patients in overcoming issues associated with tablet breaking and dose splitting.
Azopharma Company Capabilities and Services:
- Azopharma Contract Pharmaceutical Services - Integrated product development and CTM manufacturing for all dosage forms.
- ApiCross Drug Delivery Technologies - Proprietary drug delivery platforms to solve difficult molecular challenges.
- Cyanta Analytical Laboratories - Analytical chemistry and inhalation services from development to quality control testing.
- AniClin Preclinical Services - Preclinical services in support of early product development.
- IQsynthesis - Synthetic chemistry services from discovery to clinical API supplies including large scale API synthesis.
- AvivoClin Clinical Services - Human clinical pharmacology services for Phase I/II/III clinical trials.
Mr. Meeks concluded, “Azopharma Product Development Group is only one of a few organizations in the U.S. that are capable of developing a full spectrum of dosage forms from discovery through clinical trial manufacturing. By bringing together the best scientists in the field, state-of-the-art facilities and our focus on quality means that we can provide our partners a winning combination in product development.”
About Azopharma
Azopharma Product Development Group is FDA registered, DEA approved and client audited on a regular basis. Azopharma’s mission is to help our customers turn Ideas Into Cures™. In product development, it comes down to the right people, their commitment and application of experience. Partnering with Azopharma provides customers with the confidence of assured success. We welcome visits to our facility in Miramar, FL and our other sites to conduct audits or meet with our pharmaceutical scientists to outline a study that meets your specific needs. Contact us at development@azopharma.com or 954-433-7480.
About Accu-Break Pharmaceuticals, Inc.
ABP is developing ACCU-BREAK technologies for pharmaceutical tablets. The Company believes that these technologies may allow physicians to better customize treatment for their patients and that tablets utilizing ACCU-BREAK technologies will represent improved dosage forms for many types of medications.
Disclosure Notice: This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “would,” “estimate,” or “continue,” or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Shareholders are cautioned that all forward-looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; the Company’s ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of the Company’s control. No ACCU-BREAK tablets have been marketed.
Readers are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. The Company undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.
|
Contacts
Phil Meeks, Chief Executive Officer
Azopharma Product Development Group
10320 USA Today Way
Miramar FL 33025
Phone: 954-433-7480
www.azopdogroup.com
pmeeks@azopdogroup.com
|
Allan S. Kaplan, Ph.D.,Chief Executive Officer
ACCU-BREAK Pharmaceuticals, Inc.
1000 S. Pine Island Road, Suite 230
Plantation, FL 33324
Phone: 954-236-7351
Fax: 954-236-7271
www.accubreak.com
a.kaplan@accubreak.com
|